Oncology Medicines

Product Details:

USES OF IMATIB TABLET

• Treatment of Cancer

BENEFITS OF IMATIB TABLETIn Treatment of CancerIn several types of cancers like blood cancers, gastrointestinal stromal tumors, skin cancer (dermatofibrosarcoma protuberans), and bone marrow condition (aggressive systemic mastocytosis), Imatib 400 Tablet targets the specific proteins that contribute to the growth and spread of cancer cells. By stopping these proteins, the medicine slows down or even stops the growth of cancer. This helps shrink tumors, slow down their growth, and make the patients feel better.

Product Details:

What is erlotinib used for?

Erlotinib is a prescription medication used:

• For the treatment of patients with metastatic (cancer that has spread) NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations who are receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
  • You healthcare provider will use an FDA-approved test to check if you have one of these mutations. The safety and efficacy of erlotinib has not been established in patients with NSCLC whose tumors have other EGFR mutations.
• In combination with gemcitabine in patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy (first-line).

Erlotinib tablets are not recommended for use in combination with platinum- based chemotherapy.

Related/similar drugsImfinzi, Rybrevant, Opdivo, methotrexate, Keytruda, capecitabine, fluorouracilImportant information

Erlotinib can cause serious side effects, including

• Lung problems called interstitial lung disease events. Erlotinib has been shown to cause lung problems, including death. Symptoms of lung problems may include shortness of breath, cough, and fever. Erlotinib may need to be stopped if you have any of these symptoms.
• Liver and kidney problems. Erlotinib has been shown to cause severe kidney and liver problems, including death. Some people had their kidneys and liver stop working. Let your healthcare provider know if you have a history of liver or kidney disease.
• Stomach and intestinal problems called gastrointestinal perforation. Erlotinib has been shown to cause gastrointestinal perforation, which has led to death. A gastrointestinal perforation is a hole that develops in your stomach or intestine. Erlotinib patients may be at a higher risk for gastrointestinal perforation if they:
  • Are taking medicines including those that may help block the growth of blood vessels; steroids; non-steroidal anti-inflammatory drugs (NSAIDs); and certain chemotherapies. Always tell your healthcare provider about any medicines you are taking.
  • Have a history of ulcers or other stomach disease.
• Serious skin conditions. Erlotinib has been shown to cause blistering and skin peeling. This may result in other serious skin disorders or death.
• Blood, bleeding, and clotting problems. Erlotinib has been shown to cause certain blood problems and other bleeding and clotting problems. These have led to stroke and death.
• Eye disorders. Erlotinib has been shown to cause dry eyes, unusual eyelash growth, or swelling of the cornea. The cornea is the clear coating of the eyeball. This swelling may irritate or damage the eye.
• Bleeding events when taking warfarin with erlotinib. Tell your healthcare provider if you are taking a blood thinner, such as warfarin. Taking erlotinib with this medicine can cause death.
• Pregnancy. Erlotinib can harm an unborn baby. Women should use effective birth control during treatment and for at least 1 month after the last dose of erlotinib. Tell your healthcare provider if you have become pregnant, or if you think you may be pregnant, during treatment with erlotinib. Do not breast-feed during treatment with erlotinib and for 2 weeks after the final dose.